2-(Ethylamino)-1,2-diphenylethanone
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C16H17NO |
Molar mass | 239.318 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
2-(Ethylamino)-1,2-diphenylethanone (also known as α-ethylamino-deoxybenzoin, [α-(Ethylamino)benzyl]-(phenyl)-ketone and βk-Ephenidine) is a chemical compound which was first invented in 1955,[1] researched by ICI in 1969 as an antidepressant,[2] and subsequently claimed by AstraZeneca as an inhibitor of the enzyme 11β-Hydroxysteroid dehydrogenase type 1.[3] No other pharmacological data has been disclosed, though its chemical structure closely resembles that of certain designer drug compounds such as ephenidine and N-ethylhexedrone.
See also
References
- ↑ Hinderling R, Prijs B, Erlenmeyer H (1955). "Über α‐Alkylamino‐ketone". Helvetica Chimica Acta. 38 (6): 1415–1420. doi:10.1002/hlca.19550380613.
- ↑ GB 1143263, Gilman DJ, "Desyl amines and compositions thereof. gdate = 19 February 1969", assigned to ICI Ltd.
- ↑ US Abandoned 2005272036, Barton P, Clarke D, Davies C, Hargreaves R, Pease J, Rankine M, "Ketones", published 8 December 2005, assigned to AstraZeneca AB
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.